For product enquires, please call +65 6468 4948

Clinical Studies

Genacol has been a leader in its field for more than 17 years. The company continues to innovate, with the goal of offering its customers effective, new products.

Genacol continually invests in medical research to demonstrate the health benefits of its products.
We chose Dr. Haddad as scientific adviser for his knowledge, to better understand the positive features generated by hydrolysed collagen, alone or with other natural components, in the human body.
Dr. Haddad is a full professor in the Department of Pharmacology at a major Canadian university where he obtained his PhD in 1986. In the following years, he continued his postdoctoral studies (one at the University of Vienna in Austria and one in at Yale University in the United States).
Passionate and constantly seeking answers in the world of natural health, he is the author of more than 100 publications in academic journals, more than half of which focused on natural health products. These partnerships and Genacol®‘ s continuous investment in research and development has placed the company at the forefront of the industry to offer products that are both effective and innovative.



Bruyere Studies

We continually invest in research that demonstrates the benefits of our joint supplements.

Three independent studies have provided scientific confirmation that Genacol helps reduce joint pain.

The first study was conducted over a six-month period at the University of Liège and included 200 subjects, aged 50 and over, who suffered from joint pain. The objective of the study was to demonstrate the efficacy of AminoLock® Collagen (1200 mg) in relieving joint pain, as compared to a placebo.

Results: Patients who were given AminoLock® Collagen instead of a placebo obtained better scores on the VAS, a scale used to measure pain levels. The results demonstrated AminoLock® Collagen’s superior efficacy in relieving joint pain.


Parm Study

The second study was conducted at Veterans Memorial Medical Centre in the Philippines.

The objective of the study was to demonstrate the efficacy of AminoLock® Collagen in relieving knee osteoarthritis pain, as compared to a nonsteroidal anti-inflammatory drug. The study was conducted over a six-month period and included 113 patients.

Result: After 6 months of treatment, patients who were given AminoLock® Collagen reported a statistically significant reduction in pain, whereas the group given the anti-inflammatory drug reported no significant difference with respect to their pain levels.




The third clinical study was conducted at the University of Santo Tomas Hospital in the Philippines.

The objective of the study was to determine the efficacy of AminoLock® Collagen, combined with physical exercise, in treating osteoarthritis of the knee.

The placebo-controlled, triple-blind study included 109 subjects, aged 50 and older, who had experienced knee pain for over a month.

Results: The study demonstrated that AminoLock® Collagen, combined with exercise, relieves pain, improves general joint function, and produces interarticular and periarticular structural changes.

Further proof of the efficacy of AminoLock® Collagen in relieving joint pain.

Recently,, an independent organization that evaluates nutritional products in the USA, recognized Genacol’s clinical study as: ONE OF THE LARGEST STUDIES ABOUT COLLAGEN HYDROLYSATE.

The report also mentions that after 6 months of taking the collagen (Genacol) 51.6% of the participants reported a reduction in pain (Bruyere, Comp Ther Med 2012)